clopidogrel Side Effects
Also known as: Plavix
Analysis of 192,921 adverse event reports submitted to the FDA from 2003 to 2025.
Total Reports
192,921
Death-Related
21,408
11.1% of reports
Hospitalizations
88,784
46.0% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 21,408 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 6,029 |
| MYOCARDIAL INFARCTION | 1,354 |
| GASTROINTESTINAL HAEMORRHAGE | 1,320 |
| RENAL FAILURE | 1,157 |
| PNEUMONIA | 1,093 |
| CARDIAC ARREST | 1,082 |
| DYSPNOEA | 1,078 |
| CEREBRAL HAEMORRHAGE | 993 |
| ACUTE KIDNEY INJURY | 921 |
| CEREBROVASCULAR ACCIDENT | 912 |
| FALL | 780 |
| HYPOTENSION | 745 |
| CARDIAC FAILURE CONGESTIVE | 738 |
| ASTHENIA | 697 |
| CHRONIC KIDNEY DISEASE | 674 |
| NAUSEA | 664 |
| ANAEMIA | 663 |
| CARDIAC FAILURE | 659 |
| SEPSIS | 653 |
| RESPIRATORY FAILURE | 649 |
Reactions in Hospitalization Reports
Top reactions in 88,784 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| MYOCARDIAL INFARCTION | 6,791 |
| DYSPNOEA | 5,688 |
| GASTROINTESTINAL HAEMORRHAGE | 5,190 |
| ANAEMIA | 4,826 |
| FALL | 4,573 |
| CEREBROVASCULAR ACCIDENT | 4,076 |
| ASTHENIA | 3,921 |
| NAUSEA | 3,757 |
| DIZZINESS | 3,572 |
| CHEST PAIN | 3,564 |
| PNEUMONIA | 3,538 |
| DIARRHOEA | 3,458 |
| FATIGUE | 3,393 |
| ACUTE KIDNEY INJURY | 3,296 |
| HYPOTENSION | 3,217 |
| VOMITING | 2,990 |
| DRUG INTERACTION | 2,905 |
| CARDIAC FAILURE CONGESTIVE | 2,745 |
| PAIN | 2,470 |
| ACUTE MYOCARDIAL INFARCTION | 2,449 |
Nearby — Related Medications
What the FAERS Data Reveals About clopidogrel Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 192,921 voluntary reports linked to clopidogrel and its brand equivalents (Plavix), spanning 2003 through 2025. Of those, 21,408 (11.1%) listed death as an outcome and 88,784 (46.0%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 43% were female and 56% male; age distribution skews toward 75+, with 50,430 reports in that bracket. The single most reported reaction is dyspnoea with 9,917 submissions, followed by myocardial infarction and fatigue.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.